Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
This report contains market size and forecasts of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in Global, including the following market information:
- Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at 5255.3 million in 2021 and is projected to reach US$ 6545.8 million by 2028, at a CAGR of 3.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Afinitor (Everolimus) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs include Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, Roche Holding AG, Glaxosmithkline Plc, Novartis Ag and Pfizer, Inc. , etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Type, 2021 (%)
- Afinitor (Everolimus)
- Avastin (Bevacizumab)
- Cabomety (Cabozantinib)
- Inlyta (Axitinib)
- Nexavar (Sorafenib)
- Proleukin (Aldesleukin)
- Torisel (Temsirolimus)
- Sutent (Sunitinib)
- Votrient (Pazopanib)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, by Application, 2021 (%)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Active Biotech Ab
- Amgen
- Bayer AG
- Cipla Limited
- Roche Holding AG
- Glaxosmithkline Plc
- Novartis Ag
- Pfizer, Inc.
